Genomics Technique Accelerate Detection of Foodborne Bacterial Outbreaks
|
By LabMedica International staff writers Posted on 15 Dec 2016 |

Image: Bacterial colonies of Staphylococcus aureus growing on horse blood agar (Photo courtesy of OMICS International).
Diagnostic testing for foodborne pathogens relies on culture-based techniques that are not rapid enough for real-time disease surveillance and do not give a quantitative picture of pathogen abundance or the response of the natural microbiome.
Metagenomics identifies the microbes present by sequencing the entire DNA present in a sample and comparing the genomic data to a database of known microbes. In addition to identifying the bacteria present in the samples, the methodology can also measure the relative abundance of each microbial species and their virulence potential, among other things.
A collaboration of scientists from the Centers for Disease Control and Prevention (Atlanta, GA USA) and the Georgia Institute of Technology (Atlanta, GA, USA) applied shotgun metagenomics to stool samples collected from two geographically isolated foodborne outbreaks in Alabama and Colorado, where the etiologic agents were identified as distinct strains of Salmonella enterica serovar Heidelberg by culture-dependent methods. The metagenomics data provided specific information about the bacterial phenotype involved and identified a secondary Staphylococcus aureus pathogen present in two of the samples tested. Knowing the specific phenotype can help in pinpointing the origins of an outbreak, while information about the secondary infection may help explain related factors such as the severity of the infection.
The scientists were also able to rule out one species, Escherichia coli (or E. coli), because the variant present was not of a virulent type. Variants of these bacteria are present naturally in the gut microbiome (called "commensal E. coli") while other variants are notorious enteric pathogens. Metagenomics showed the abundant E. coli population in the outbreak samples was probably commensal, and its growth may have been accelerated when conditions became more favorable during the Salmonella infection. In the two cases evaluated, scientists were able to determine that although the symptoms were similar, the outbreaks were caused by different variants of Salmonella and therefore were probably not connected.
Andrew D. Huang, PhD, a microbiologist/ bioinformatician and lead author of the study said, “Currently, the most advanced DNA fingerprinting method, whole genome sequencing, requires first pulling out, or isolating in a pure culture, the bacteria that made a person sick to generate a fingerprint. Metagenomics differs from whole genome sequencing because it could allow us to sequence the entire DNA in a patient's sample. It could allow us to skip the isolation steps and go directly from a stool sample to a highly detailed DNA fingerprint of the bacteria that made you sick. This method saves time and provides more detail that could be helpful for diagnosing a patient and identifying an outbreak.” The study was published on November 23, 2016, in the journal Applied and Environmental Microbiology.
Related Links:
Centers for Disease Control and Prevention
Georgia Institute of Technology
Metagenomics identifies the microbes present by sequencing the entire DNA present in a sample and comparing the genomic data to a database of known microbes. In addition to identifying the bacteria present in the samples, the methodology can also measure the relative abundance of each microbial species and their virulence potential, among other things.
A collaboration of scientists from the Centers for Disease Control and Prevention (Atlanta, GA USA) and the Georgia Institute of Technology (Atlanta, GA, USA) applied shotgun metagenomics to stool samples collected from two geographically isolated foodborne outbreaks in Alabama and Colorado, where the etiologic agents were identified as distinct strains of Salmonella enterica serovar Heidelberg by culture-dependent methods. The metagenomics data provided specific information about the bacterial phenotype involved and identified a secondary Staphylococcus aureus pathogen present in two of the samples tested. Knowing the specific phenotype can help in pinpointing the origins of an outbreak, while information about the secondary infection may help explain related factors such as the severity of the infection.
The scientists were also able to rule out one species, Escherichia coli (or E. coli), because the variant present was not of a virulent type. Variants of these bacteria are present naturally in the gut microbiome (called "commensal E. coli") while other variants are notorious enteric pathogens. Metagenomics showed the abundant E. coli population in the outbreak samples was probably commensal, and its growth may have been accelerated when conditions became more favorable during the Salmonella infection. In the two cases evaluated, scientists were able to determine that although the symptoms were similar, the outbreaks were caused by different variants of Salmonella and therefore were probably not connected.
Andrew D. Huang, PhD, a microbiologist/ bioinformatician and lead author of the study said, “Currently, the most advanced DNA fingerprinting method, whole genome sequencing, requires first pulling out, or isolating in a pure culture, the bacteria that made a person sick to generate a fingerprint. Metagenomics differs from whole genome sequencing because it could allow us to sequence the entire DNA in a patient's sample. It could allow us to skip the isolation steps and go directly from a stool sample to a highly detailed DNA fingerprint of the bacteria that made you sick. This method saves time and provides more detail that could be helpful for diagnosing a patient and identifying an outbreak.” The study was published on November 23, 2016, in the journal Applied and Environmental Microbiology.
Related Links:
Centers for Disease Control and Prevention
Georgia Institute of Technology
Latest Microbiology News
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








